John T. Carpenter

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Marc L. Citron, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2003 · 1.6K citations

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

Robert B. Diasio, T L Beavers, John T. Carpenter · Journal of Clinical Investigation · 1988 · 499 citations · Full text

Genetics, Toxicological Mechanism, Oxidative Stress +17

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

Laura J. Esserman, Donald A. Berry, Angela DeMichele et al. · Journal of Clinical Oncology · 2012 · 435 citations · Full text

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

Barry Harris, John T. Carpenter, Robert B. Diasio · Cancer · 1991 · 223 citations · Full text

Genetics, Adjuvant Chemotherapy, Pathology +16